-transparent.png){kind=logo}
Twenty-four patients with lung cancer receiving cis-platinum chemotherapy were entered in an antiemetic randomized crossover trial. The effects of high-dose metoclopramide and droperidol (regimen I) were compared with those obtained with a combination of high-dose metoclopramide, droperidol and methylprednisolone (regimen II). Three patients (12.5%) treated with regimen I and 10 (43.5%) treated with regimen II had no vomiting at all (p less than 0.05). Patient preference was significantly in favor of regimen II (p less than 0.05). No Severe side effects were observed. A further trial is necessary to determine the optimal dosage and scheduling of the available agents.
Related Publications
M Fujii, and
K Kiura, and
M Tamai, and
K Okabe, and
H Toki
January 1982,
Oncology nursing forum,
M Fujii, and
K Kiura, and
M Tamai, and
K Okabe, and
H Toki
December 1989,
Journal of chemotherapy (Florence, Italy),
M Fujii, and
K Kiura, and
M Tamai, and
K Okabe, and
H Toki
May 1985,
Gynecologic oncology,
M Fujii, and
K Kiura, and
M Tamai, and
K Okabe, and
H Toki
July 1986,
Gan to kagaku ryoho. Cancer & chemotherapy,
M Fujii, and
K Kiura, and
M Tamai, and
K Okabe, and
H Toki
January 1989,
Oncology,
M Fujii, and
K Kiura, and
M Tamai, and
K Okabe, and
H Toki
January 1984,
Cancer chemotherapy and pharmacology,
M Fujii, and
K Kiura, and
M Tamai, and
K Okabe, and
H Toki
October 1985,
Tumori,
M Fujii, and
K Kiura, and
M Tamai, and
K Okabe, and
H Toki
February 1983,
Tumori,
M Fujii, and
K Kiura, and
M Tamai, and
K Okabe, and
H Toki
July 1985,
Gynecologic oncology,
M Fujii, and
K Kiura, and
M Tamai, and
K Okabe, and
H Toki
January 1992,
Oncology,
